- Home
- HUMA vs TERN Comparison
HUMA vs TERN Comparison
Compare HUMA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- TERN
- Stock Information
- Founded
- HUMA 2004
- TERN 2017
- Country
- HUMA United States
- TERN United States
- Employees
- HUMA N/A
- TERN N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- HUMA Health Care
- TERN Health Care
- Exchange
- HUMA Nasdaq
- TERN Nasdaq
- Market Cap
- HUMA 577.7M
- TERN 499.4M
- IPO Year
- HUMA N/A
- TERN 2021
- Fundamental
- Price
- HUMA $4.64
- TERN $5.86
- Analyst Decision
- HUMA Strong Buy
- TERN Buy
- Analyst Count
- HUMA 7
- TERN 5
- Target Price
- HUMA $13.14
- TERN $18.30
- AVG Volume (30 Days)
- HUMA 6.3M
- TERN 2.1M
- Earning Date
- HUMA 11-08-2024
- TERN 11-12-2024
- Dividend Yield
- HUMA N/A
- TERN N/A
- EPS Growth
- HUMA N/A
- TERN N/A
- EPS
- HUMA N/A
- TERN N/A
- Revenue
- HUMA N/A
- TERN N/A
- Revenue This Year
- HUMA N/A
- TERN N/A
- Revenue Next Year
- HUMA $6,438.24
- TERN N/A
- P/E Ratio
- HUMA N/A
- TERN N/A
- Revenue Growth
- HUMA N/A
- TERN N/A
- 52 Week Low
- HUMA $2.48
- TERN $4.32
- 52 Week High
- HUMA $9.97
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- HUMA 53.53
- TERN 41.20
- Support Level
- HUMA $3.37
- TERN $5.46
- Resistance Level
- HUMA $4.42
- TERN $7.14
- Average True Range (ATR)
- HUMA 0.50
- TERN 0.52
- MACD
- HUMA 0.01
- TERN -0.04
- Stochastic Oscillator
- HUMA 37.35
- TERN 20.00
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.